Comparing 2 hypotheses side-by-side
## Mechanistic Overview Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics starts from the claim that modulating ANXA1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The fundamental mechanism underlying this therapeutic approach centers on the precise molecular orchestration of synaptic maintenance through phosphatidylserine (PS) exposure regulation. Under normal physiologica
## Mechanistic Overview Purinergic P2Y12 Inverse Agonist Therapy starts from the claim that modulating P2RY12 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: "**Molecular Mechanism and Rationale** The P2Y12 receptor, encoded by the P2RY12 gene, represents a critical component of microglial surveillance and activation machinery in the central nervous system. This Gi/Go-coupled purinergic receptor responds to extracellular ad
This summary checks where the selected hypotheses point toward the same target or mechanism, and where they pull in opposite directions.
| Dimension | Synaptic Phosphatidylserine Ma | Purinergic P2Y12 Inverse Agoni |
|---|---|---|
| Mechanistic | 0.700 | 0.750 |
| Evidence | 0.450 | 0.650 |
| Novelty | 0.450 | 0.800 |
| Feasibility | 0.500 | 0.700 |
| Impact | 0.600 | 0.720 |
| Druggability | 0.700 | 0.850 |
| Safety | 0.450 | 0.550 |
| Competition | 0.814 | 0.750 |
| Data | 0.712 | 0.600 |
| Reproducible | 0.150 | 0.580 |
| KG Connect | 0.695 | 0.705 |
No evidence citations yet
No evidence citations yet
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
4 rounds · quality: 0.95
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Novel Therapeutic Hypotheses for Synaptic Pruning in Early Alzheimer's Disease ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Description:** Engineer synthetic C1q mimetics that bind to sy...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
# Critical Evaluation of Synaptic Pruning Therapeutic Hypotheses ## Hypothesis 1: Complement C1q Mimetic Decoy Therapy **Specific Weaknesses:** - **Selectivity Problem:** C1q has essential physiolog...
Curated mechanism pathway diagrams from expert analysis
graph TD
A["Synaptic Stress Triggers"]
B["ATP11C Translocase Dysfunction"]
C["PS Externalization"]
D["MFG-E8 Bridge Formation"]
E["Microglial PSR Activation"]
F["ANXA1 Mimetic Intervention"]
G["PS Masking"]
H["Phagocytic Signal Inhibition"]
I["Synaptic Preservation"]
J["Microglial Activation"]
K["Complement C1q Deposition"]
L["Synaptic Pruning"]
M["Neuronal Loss"]
N["Cognitive Decline"]
O["Neuroprotective Outcome"]
A -->|"induces"| B
B -->|"causes"| C
C -->|"recruits"| D
D -->|"activates"| E
E -->|"triggers"| J
J -->|"promotes"| K
K -->|"enhances"| L
L -->|"leads to"| M
M -->|"results in"| N
F -->|"binds to"| C
F -->|"blocks"| G
G -->|"prevents"| H
H -->|"maintains"| I
I -->|"achieves"| O
style A fill:#ffd54f
style B fill:#ef5350
style C fill:#ef5350
style D fill:#ef5350
style E fill:#ef5350
style F fill:#81c784
style G fill:#4fc3f7
style H fill:#4fc3f7
style I fill:#4fc3f7
style J fill:#ef5350
style K fill:#ef5350
style L fill:#ef5350
style M fill:#ef5350
style N fill:#ef5350
style O fill:#ffd54f
graph TD
A["Extracellular
ADP/ATP Release"] --> B["P2Y12 Receptor
Activation"]
B --> C["Gi/Go Protein
Coupling"]
C --> D["Adenylyl Cyclase
Inhibition"]
D --> E["Decreased cAMP
Levels"]
E --> F["PI3K/Akt Pathway
Activation"]
F --> G["Rho GTPase
Activation
(Rac1/CDC42)"]
G --> H["Actin Cytoskeletal
Reorganization"]
H --> I["Microglial Process
Extension"]
I --> J["Enhanced Synaptic
Surveillance"]
J --> K["Excessive Synaptic
Pruning"]
K --> L["Neuronal Network
Dysfunction"]
L --> M["Neurodegeneration
Progression"]
N["P2Y12 Inverse
Agonist Therapy"] --> B
N -->|"Blocks"| C
O["Therapeutic
Outcome"] --> L
classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8
class A,B,C,D,E normal
class N therapeutic
class I,J,K,L,M pathology
class O outcome
class F,G,H molecular